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Background
Despite improvements in treatment options, metastatic
breast cancer (MBC) remains an incurable disease. In our
recent Phase I immunotherapy (IT) trial in 23 women
with MBC, 8 infusions of activated T cells (ATC) armed
with anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)
given in combination with interleukin-2 (IL-2) and gran-
ulocyte-macrophage colony stimulating factor (GM-CSF)
induced specific anti-breast cancer (BrCa) cytotoxicity
and increased IL-12 and Th1 cytokines in the serum
1.
This study investigated whether specific cellular and
humoral anti-BrCa immunity is induced by infusions of
HER2Bi bispecific antibody armed T cells (BATs) could
be transferred after high dose chemotherapy (HDC) and
stem cell transplant (SCT).
Methods
T cell were activated with OKT3 and expanded in IL-2.
ATC were harvested, armed with HER2Bi, and cryopre-
served in 8 doses for twice weekly infusions for 4 weeks
along with IL-2 and GM-CSF. Seven to 14 days after the
last infusion of BATs, the patient was leukapheresed to
obtain immune T cells. Immune ATC were harvested
and cryopreserved for multiple infusions after the HDC
and SCT. Cellular and humoral immune responses were
monitored up to 24 months.
Results
Six of 8 MBC patients enrolled in the protocol, com-
pleted the protocol and were evaluable for transfer of
cellular and humoral immunity. No dose-limiting events
for the infusions, delays in engraftment, and life-threa-
tening infections were observed. Five of 6 evaluable
patients exhibited increased anti-BrCa cytotoxicity and
IFN-g Elispots after vaccination with BATs and up to 12
months post SCT. Serum and culture supernatantsfrom
in vitro antibody synthesis assay showed gradual
increases in anti-SK-BR-3 IgG levels after SCT. Serum
cytokine profile showed increases in IL-12 and Th1 cyto-
kines. One of 6 evaluable patients who rapidly pro-
gressed showed poor immune responses (CTL and IFN-
g Elispots), had high serum levels of Th2 cytokines and
no evidence of transfer of immunity. Flow cytometry
analysis of Vb repertoirepattern in PBMC collected post
IT and post SCT indicate transfer of the major Vb
clones post SCT.
Conclusions
This pilot study suggests that optimal adoptive transfer of
cellular and humoral immunity induced by BAT infusions
using ex vivo expanded immune anti-breast cancer T cells
after SCT accelerates not only immune reconstitution but,
more importantly, enhances reconstruction of anti-tumor
cellular and humoral immunity after HDC and SCT to
achieve maximal tumor reduction and regulatory T cell
ablation.1Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
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